Publication Name	World Journal of Clinical Cases
Manuscript ID	58044
Country	China

Category	Medical Informatics
Manuscript Type	Observational Study
Article Title	No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
Manuscript Source	Unsolicited Manuscript
All Author List	Jiang-Hua Zhou, Bin Wu, Wen-Xin Wang, Fang Lei, Xu Cheng, Juan-Juan Qin, Jing-Jing Cai, Xiao‐Jing Zhang, Feng Zhou, Ye-Mao Liu, Hao-Miao Li, Li-Hua Zhu, Zhi‐Gang She, Xin Zhang, Juan Yang and Hong-Liang Li
Funding Agency and Grant Number	Funding Agency Grant Number National Key R&D Program of China 2019YFC2004702 National Key R&D Program of China 2020YFC0845500 the National Science Foundation of China 81970070 the National Science Foundation of China 81970011 the Hubei Science and Technology Support Project 2019BFC582 the Hubei Science and Technology Support Project 2018BEC473
Corresponding Author	Hong-Liang Li, MD, PhD, Professor, Department of Cardiology, Renmin Hospital of Wuhan University; Institute of Model Animal of Wuhan University, No. 115 Donghu Road, Wuchang District, Wuhan 430071, Hubei Province, China. lihl@whu.edu.cn
Key Words	COVID-19; SARS-CoV-2; DPP4 inhibitors; Diabetes; Glucose-control; Adverse effects
Core Tip	Our study illuminated that there were no significant associations between in-hospital use of dipeptidyl peptidase-4 (DPP4) inhibitor (DPP4i) and 28-d all-cause mortality or multiorgan injury. In addition, the glucose control effects, inflammatory response, and associated adverse events were also comparable between patients in the DPP4i group and non-DPP4i group. These data provided direct clinical evidence to support the continuation of DPP4i therapy in diabetic patients with coronavirus disease 2019 (COVID-19). Moreover, this work paves the way for prospective studies and randomized controlled clinical trials on DPP4 inhibitor therapy for COVID-19.
Citation	Zhou JH, Wu B, Wang WX, Lei F, Cheng X, Qin JJ, Cai JJ, Zhang X, Zhou F, Liu YM, Li HM, Zhu LH, She Z, Zhang X, Yang J, Li HL. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19. World J Clin Cases 2020; 8(22): 5576-5588

Received	2020-07-06 14:47
Peer-Review Started	2020-07-06 14:48
To Make the First Decision
Return for Revision	2020-08-11 02:11
Revised	2020-08-20 14:03
Second Decision	2020-09-24 12:36
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2020-09-25 05:17
Articles in Press	2020-09-25 05:17
Publication Fee Transferred
Edit the Manuscript by Language Editor	2020-10-07 13:03
Typeset the Manuscript	2020-11-20 01:18

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com